When was Acepodia founded?

Acepodia was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Acepodia located?

Acepodia is headquartered in Alameda, United States.

How many employees does Acepodia have?

As of Jul 31, 2026, the latest employee count at Acepodia is 60.

Is Acepodia a funded company?

Acepodia is a funded company, having raised a total of $256M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 16, 2021.

When was the latest funding round of Acepodia?

Acepodia's latest funding was a $***** Series D round on Jun 06, 2023, with participation from 1 investor.

Where does Acepodia rank among its competitors?

Acepodia ranks 203rd amongst 3294 active competitors, of which 1126 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Acepodia?

Acepodia's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Acepodia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Acepodia is developing cancer immunotherapy using antibody cell conjugation technology. The company's proprietary immune cells are developed by combining novel and well-established targeting mechanisms using Antibody-Cell Conjugation (ACC) and Chimeric Antigen Receptor (CAR) technology. It forms the antigen-antibody complex and helps to eradicate cancer cells. Its pipeline candidate includes ACE1702 is under the preclinical stage that will use to treat ovarian and breast cancer. Its other products include ACE1708 and AAT1805 to treat lymphoma.

Website: www.acepodia.com/
Social
Email ID: *****@acepodiabio.com
Phone Number: +886 **********

Key Metrics

Founded Year

2017

Location

Alameda, United States

Stage

Public

Total Funding

$256M in 3 rounds

Latest Funding Round

Series D, Jun 06, 2023, $*****

Investors

CDIB Capital & 11 more

Ranked

203^rd among 3294 active competitors

Employee Count

60 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3024 more

Exit Details

Public

View Acepodia's full profile

Acepodia got listed on Aug 08, 2023.

Click here to take a look at Acepodia's IPO in detail

Acepodia has raised a total funding of $256M over 3 rounds. Its first funding round was on Mar 16, 2021. Its latest funding round was a Series D round on Jun 06, 2023 for $*****. 1 investor participated in its latest round. Acepodia has 9 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Acepodia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 06, 2023	7618307	Series D	8777217	5006569	2641702	4624081
Dec 02, 2021	9302360	Series C	7943994	1773899	7053771	8384479
Mar 16, 2021	5408241	Series B	5840322	6521038	Ridgeback Capital Management & 5 more	Samuel Chen & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Acepodia's funding rounds and investors

The founders of Acepodia are Patrick Y Yang and Sonny Hsiao.

Here are the details of Acepodia's key team members:

Patrick Y Yang: Founder of Acepodia.
Sonny Hsiao: Founder of Acepodia.

View details of Acepodia's Founder profiles and Board Members

Acepodia's employee count trend

Acepodia has 60 employees as of Jul 26. Here is Acepodia's employee count trend over the years:

Uncover Acepodia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acepodia include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Acepodia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
203rd	Acepodia 2017, Alameda (United States), Public	Developer of cancer immunotherapy to treat ovarian and breast cancer	$256M	Ridgeback Capital Management, M Venture Investment ... & 10 others	59/100